Abstract
The viaB locus coding for the Vi antigen of Salmonella typhi Ty2 was cloned on a 40.6-kilobase fragment into the cosmid vector pHC79. The live, oral, attenuated Vi-negative S. typhi Ty21a vaccine strain was transformed with the recombinant cosmid encoding the viaB locus. Homologous recombination of the viaB locus into the chromosome of S. typhi Ty21a was induced by UV irradiation, and Vi-positive recombinants were selected in the presence of D-cycloserine. One such isolate, termed WR4103, contained no plasmids or the attendant antibiotic resistance markers and expressed the Vi antigen stably. Vi antigen extracted from WR4103 was immunologically indistinguishable from Vi antigen purified from S. typhi Ty2. The only detectable difference between Ty21a and WR4103 was in the production of Vi antigen. The mean lethal doses of Ty21a and WR4103 for mice were nearly identical. Immunization of mice with WR4103 engendered a Vi antibody response and afforded complete protection against fatal infection with virulent S. typhi Ty2. Thus, S. typhi WR4103 may serve as an improved oral vaccine for protection against typhoid fever.
Full text
PDF





Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Acharya I. L., Lowe C. U., Thapa R., Gurubacharya V. L., Shrestha M. B., Cadoz M., Schulz D., Armand J., Bryla D. A., Trollfors B. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med. 1987 Oct 29;317(18):1101–1104. doi: 10.1056/NEJM198710293171801. [DOI] [PubMed] [Google Scholar]
- Baron L. S., Kopecko D. J., McCowen S. M., Snellings N. J., Johnson E. M., Reid W. C., Life C. A. Genetic and molecular studies of the regulation of atypical citrate utilization and variable Vi antigen expression in enteric bacteria. Basic Life Sci. 1982;19:175–194. doi: 10.1007/978-1-4684-4142-0_16. [DOI] [PubMed] [Google Scholar]
- Black R., Levine M. M., Young C., Rooney J., Levine S., Clements M. L., O'Donnell S., Hugues T., Germanier R. Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules. Dev Biol Stand. 1983;53:9–14. [PubMed] [Google Scholar]
- Cancellieri V., Fara G. M. Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine. J Infect Dis. 1985 Mar;151(3):482–484. doi: 10.1093/infdis/151.3.482. [DOI] [PubMed] [Google Scholar]
- Cryz S. J., Fürer E. Further characterization of the Salmonella typhi Ty21a vaccine strain. J Infect Dis. 1988 Jun;157(6):1276–1279. doi: 10.1093/infdis/157.6.1276. [DOI] [PubMed] [Google Scholar]
- Cryz S. J., Jr, Fürer E., Levine M. M. Zur Wirksamkeit des oralen, attenuierten Lebendimpfstoffes Salmonella typhi Ty 21a in kontrollierten Feldversuchen. Schweiz Med Wochenschr. 1988 Apr 2;118(13):467–470. [PubMed] [Google Scholar]
- D'Amelio R., Tagliabue A., Nencioni L., Di Addario A., Villa L., Manganaro M., Boraschi D., Le Moli S., Nisini R., Matricardi P. M. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect Immun. 1988 Oct;56(10):2731–2735. doi: 10.1128/iai.56.10.2731-2735.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Edelman R., Levine M. M. Summary of an international workshop on typhoid fever. Rev Infect Dis. 1986 May-Jun;8(3):329–349. doi: 10.1093/clinids/8.3.329. [DOI] [PubMed] [Google Scholar]
- Germanier R., Füer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975 May;131(5):553–558. doi: 10.1093/infdis/131.5.553. [DOI] [PubMed] [Google Scholar]
- Germanier R., Fürer E. Immunity in experimental salmonellosis. II. Basis for the avirulence and protective capacity of gal E mutants of Salmonella typhimurium. Infect Immun. 1971 Dec;4(6):663–673. doi: 10.1128/iai.4.6.663-673.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hone D. M., Attridge S. R., Forrest B., Morona R., Daniels D., LaBrooy J. T., Bartholomeusz R. C., Shearman D. J., Hackett J. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun. 1988 May;56(5):1326–1333. doi: 10.1128/iai.56.5.1326-1333.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Klugman K. P., Gilbertson I. T., Koornhof H. J., Robbins J. B., Schneerson R., Schulz D., Cadoz M., Armand J. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 1987 Nov 21;2(8569):1165–1169. doi: 10.1016/s0140-6736(87)91316-x. [DOI] [PubMed] [Google Scholar]
- LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
- Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
- Lederberg E. M., Cohen S. N. Transformation of Salmonella typhimurium by plasmid deoxyribonucleic acid. J Bacteriol. 1974 Sep;119(3):1072–1074. doi: 10.1128/jb.119.3.1072-1074.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Levine M. M., Ferreccio C., Black R. E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987 May 9;1(8541):1049–1052. doi: 10.1016/s0140-6736(87)90480-6. [DOI] [PubMed] [Google Scholar]
- NIKAIDO H. Galactose-sensitive mutants of Salmonella. I. Metabolism of galactose. Biochim Biophys Acta. 1961 Apr 15;48:460–469. doi: 10.1016/0006-3002(61)90044-0. [DOI] [PubMed] [Google Scholar]
- Robbins J. D., Robbins J. B. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis. 1984 Sep;150(3):436–449. doi: 10.1093/infdis/150.3.436. [DOI] [PubMed] [Google Scholar]
- Tagliabue A., Nencioni L., Caffarena A., Villa L., Boraschi D., Cazzola G., Cavalieri S. Cellular immunity against Salmonella typhi after live oral vaccine. Clin Exp Immunol. 1985 Nov;62(2):242–247. [PMC free article] [PubMed] [Google Scholar]
- Tagliabue A., Villa L., De Magistris M. T., Romano M., Silvestri S., Boraschi D., Nencioni L. IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. J Immunol. 1986 Sep 1;137(5):1504–1510. [PubMed] [Google Scholar]
- Takeuchi A. Electron microscope studies of experimental Salmonella infection. I. Penetration into the intestinal epithelium by Salmonella typhimurium. Am J Pathol. 1967 Jan;50(1):109–136. [PMC free article] [PubMed] [Google Scholar]
- Tsai C. M., Frasch C. E. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem. 1982 Jan 1;119(1):115–119. doi: 10.1016/0003-2697(82)90673-x. [DOI] [PubMed] [Google Scholar]
- WHITESIDE R. E., BAKER E. E. The Vi antigens of the Enterobacteriaceae. V. Serologic differences of Vi antigens revealed by deacetylation. J Immunol. 1961 May;86:538–542. [PubMed] [Google Scholar]
- Wahdan M. H., Sérié C., Cerisier Y., Sallam S., Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis. 1982 Mar;145(3):292–295. doi: 10.1093/infdis/145.3.292. [DOI] [PubMed] [Google Scholar]